Express News | Vistagen Expands Global Intellectual Property Portfolio With New Patents For PH80 Nasal Spray; Investigational Treatment For Migraine, Hot Flashes Due To Menopause, Premenstrual Dysphoric Disorder, And Dysmenorrhea
Express News | Vistagen Therapeutics Inc: All of New Patents Are Expected to Be in Effect Until 2040
Express News | Vistagen Broadens Ph80 Global Intellectual Property Portfolio With New Patents for the Treatment of Migraine
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q4 2024 Earnings Conference
VistaGen Therapeutics | 10-K: Annual report
VistaGen Therapeutics GAAP EPS of -$1.52 Misses by $1.16, Revenue of $1.06M Beats by $0.86M
Express News | Vistagen Reports FY24 Net Loss Of $(29.4)M Vs $(59.2)M Last Year
Express News | Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Notable Earnings After Tuesday's Close
VistaGen Therapeutics Q4 Earnings Preview
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
Vistagen to Present at the Jefferies Global Healthcare Conference
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Express News | Vistagen Therapeutics Inc: Ph15 Was Safe and Well-Tolerated With an Adverse Event Profile Similar to Placebo
Express News | Vistagen Therapeutics Inc: Ph15 Nasal Spray Demonstrates Statistically Significant Efficacy Versus Placebo and Caffeine
Express News | Vistagen Announces Positive Results From Phase 2a Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue